KOPRANKopran Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 2.8 this quarter.
Momentum from moving averages, Supertrend and RSI.
3 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
3 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹211 Cr | ₹4 Cr | 4.51% | 2.08% | ₹0.91 | 2.4x |
| Q1 FY2027 | ₹154 Cr | ₹7 Cr | 6.51% | 4.35% | ₹1.39 | 3.7x |
| Q4 FY2026 | ₹234 Cr | ₹19 Cr | 12.15% | 8.06% | ₹3.91 | 9.0x |
| Q3 FY2026 | ₹194 Cr | ₹9 Cr | 6.86% | 4.80% | ₹1.93 | 5.0x |
| Q2 FY2026 | ₹118 Cr | ₹-10 Cr | -6.07% | -8.40% | ₹-2.05 | -4.5x |
| Q1 FY2026 | ₹135 Cr | ₹7 Cr | 7.29% | 5.50% | ₹1.54 | 4.9x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.